NCT04075175View on ClinicalTrials.gov

Evaluate the Safety Pharmacokinetics of a Human Monoclonal Antibody S315 Against Diphtheria Toxin in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

April 23, 2019

Primary Completion Date

October 7, 2019

Study Completion Date

October 7, 2019

Conditions
Diphtheria
Interventions
DRUG

S315

Human monoclonal antibody against Diphtheria Toxin

DRUG

0.9% Sodium Chloride (NaCl)

Placebo 0.9% Sodium Chloride (NaCl)

Trial Locations (1)

21225

Parexel Early Phase Clinical Unit, Baltimore

Sponsors

Lead Sponsor

MassBiologics
All Listed Sponsors
lead

MassBiologics

OTHER

NCT04075175 - Evaluate the Safety Pharmacokinetics of a Human Monoclonal Antibody S315 Against Diphtheria Toxin in Healthy Subjects | Biotech Hunter | Biotech Hunter